Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504046 · ClinicalTrials.gov registry record · Phase 2
Safety and Feasibility Evaluation of the APS APP
A Phase 2 study, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03504046: Completed Phase 2 study, sponsored by Sansum Diabetes Research Institute.
NCT03504046 is a Phase 2 study that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03504046, a Phase 2 study, has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This clinical trial is a safety and feasibility study to assess the performance of artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the APS APP platform.
Primary Outcome
Time in target glucose range overall
Interventions
- DEVICE Artificial Pancreas App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 2 |
What the finished NCT03504046 record still lists
NCT03504046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Artificial Pancreas App is the first listed.
NCT03504046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03504046 about?
NCT03504046 is a clinical study titled "Safety and Feasibility Evaluation of the APS APP". This clinical trial is a safety and feasibility study to assess the performance of artificial pancreas (AP) system using the Zone Model Predictive control (Zone-MPC) and Health Monitoring System (HMS) algorithms embedded into the APS APP platform.
What is the current status of trial NCT03504046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2018-02-28. Estimated completion is 2018-09-04.
What interventions are being tested in trial NCT03504046?
The interventions under investigation include: Artificial Pancreas App (DEVICE).
Who is sponsoring clinical trial NCT03504046?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03504046's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI